Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc

Bullboard Posts

Post by thisisriskystufon Oct 29, 2018 7:17pm

211 Views

Post# 28891138

At Walletinvestor.com

we predict future values with technical analysis for wide selection of stocks like Theratechnologies Inc (THERF). If you are looking for stocks with good return, Theratechnologies Inc can be a profitable investment option. Theratechnologies Inc quote is equal to 5.940 USD at 2018-10-29. Based on our forecasts, a long-term increase is expected, the "THERF" stock price prognosis for 2023-10-18 is 20.402 USD With a 5-year investment, the revenue is expected to be around +243.47%. Your current $100 investment may be up to $343.47 in 2023.

Bullboard Posts

Hempalta acquires controlling interest in Hemp Carbon Standard